LTR Pharma Issues New Shares for ED Nasal Spray

LTR Pharma Limited (AU:LTP) has released an update.

LTR Pharma Limited has announced the issuance of 14,383,562 new shares without investor disclosure, in accordance with Section 708A of the Corporations Act. The company, which specializes in men’s health through an innovative nasal spray for Erectile Dysfunction called SPONTAN®, confirms adherence to the necessary provisions of the Corporations Act and reports no excluded information as per the relevant sections. This move is expected to bolster the company’s efforts to revolutionize ED treatment with a fast-acting nasal spray.

For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.